These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand. Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431 [TBL] [Abstract][Full Text] [Related]
8. Inter-laboratory variation in cerebrospinal fluid biomarkers for Alzheimer's disease: united we stand, divided we fall. Mattsson N; Blennow K; Zetterberg H Clin Chem Lab Med; 2010 May; 48(5):603-7. PubMed ID: 20201744 [TBL] [Abstract][Full Text] [Related]
9. Comparison of two analytical platforms for the clinical qualification of Alzheimer's disease biomarkers in pathologically-confirmed dementia. Le Bastard N; Coart E; Vanderstichele H; Vanmechelen E; Martin JJ; Engelborghs S J Alzheimers Dis; 2013; 33(1):117-31. PubMed ID: 22936010 [TBL] [Abstract][Full Text] [Related]
11. Supportive CSF biomarker evidence to enhance the National Institute on Aging-Alzheimer's Association criteria for diagnosis of Alzheimer's type dementia--a study from Southern India. Huded CB; Bharath S; Chandra SR; Sivakumar PT; Varghese M; Subramanian S Asian J Psychiatr; 2015 Feb; 13():44-7. PubMed ID: 25468261 [TBL] [Abstract][Full Text] [Related]
12. Biomarkers for Alzheimer's disease: current status and prospects for the future. Blennow K; Zetterberg H J Intern Med; 2018 Dec; 284(6):643-663. PubMed ID: 30051512 [TBL] [Abstract][Full Text] [Related]
13. Discriminatory and predictive capabilities of enzyme-linked immunosorbent assay and multiplex platforms in a longitudinal Alzheimer's disease study. Jongbloed W; Kester MI; van der Flier WM; Veerhuis R; Scheltens P; Blankenstein MA; Teunissen CE Alzheimers Dement; 2013 May; 9(3):276-83. PubMed ID: 23110867 [TBL] [Abstract][Full Text] [Related]
14. Cerebrospinal Fluid Biomarkers for Early and Differential Alzheimer's Disease Diagnosis. Bjerke M; Engelborghs S J Alzheimers Dis; 2018; 62(3):1199-1209. PubMed ID: 29562530 [TBL] [Abstract][Full Text] [Related]
15. Cerebrospinal Fluid Biomarkers in Alzheimer's Disease: An Invaluable Tool for Clinical Diagnosis and Trial Enrichment. Parnetti L; Eusebi P J Alzheimers Dis; 2018; 64(s1):S281-S287. PubMed ID: 29562517 [TBL] [Abstract][Full Text] [Related]
16. Different cerebrospinal fluid levels of Alzheimer-type biomarker Aβ42 between general paresis and asymptomatic neurosyphilis. Luo X; Shi H; Hou L; Zhong X; Chen X; Zhang Y; Zheng D; Tan Y; Hu G; Mu N; Chen J; Fang Y; He H; Ning Y Eur J Neurol; 2015 May; 22(5):853-8. PubMed ID: 25707998 [TBL] [Abstract][Full Text] [Related]
17. Idiopathic normal pressure hydrocephalus has a different cerebrospinal fluid biomarker profile from Alzheimer's disease. Jingami N; Asada-Utsugi M; Uemura K; Noto R; Takahashi M; Ozaki A; Kihara T; Kageyama T; Takahashi R; Shimohama S; Kinoshita A J Alzheimers Dis; 2015; 45(1):109-15. PubMed ID: 25428256 [TBL] [Abstract][Full Text] [Related]
18. Cerebrospinal fluid biomarkers for Alzheimer’s disease: diagnostic performance in a homogeneous mono-center population. Johansson P; Mattsson N; Hansson O; Wallin A; Johansson JO; Andreasson U; Zetterberg H; Blennow K; Svensson J J Alzheimers Dis; 2011; 24(3):537-46. PubMed ID: 21297262 [TBL] [Abstract][Full Text] [Related]
19. Cystatin C levels are positively correlated with both Abeta42 and tau levels in cerebrospinal fluid in persons with Alzheimer's disease, mild cognitive impairment, and healthy controls. Sundelöf J; Sundström J; Hansson O; Eriksdotter-Jönhagen M; Giedraitis V; Larsson A; Degerman-Gunnarsson M; Ingelsson M; Minthon L; Blennow K; Kilander L; Basun H; Lannfelt L J Alzheimers Dis; 2010; 21(2):471-8. PubMed ID: 20555147 [TBL] [Abstract][Full Text] [Related]
20. Comparison between clinical diagnosis and CSF biomarkers of Alzheimer disease in elderly patients with late onset psychosis: Helsinki Old Age Psychosis Study (HOPS). Seppälä TT; Louhija UM; Appelberg B; Herukka SK; Juva K Am J Geriatr Psychiatry; 2014 Sep; 22(9):908-16. PubMed ID: 23597931 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]